IDiyas

For the Inventor, By the Inventor

Carmel, IN, United States of America

Jon Kevin Reel

USPTO Granted Patents = 45 


 

Average Co-Inventor Count = 8.3

ph-index = 10

Forward Citations = 428(Granted Patents)


Location History:

  • Indianapolis, IN (US) (1991 - 1996)
  • Carmel, IN (US) (1994 - 2016)

Company Filing History:

goldMedal29 out of 4,442 
 
Eli Lilly and Company
 patents
silverMedal4 out of 35 
 
Athena Neurosciences, Inc.
 patents
bronzeMedal2 out of 202 
 
Elan Pharmaceuticals, Inc.
 patents
4. 15 out of 832,680 
Other
 patents
where one patent can have more than one assignee

Years Active: 1991-2016

Loading Chart...
Loading Chart...
Loading Chart...
45 patents (USPTO):Explore Patents
1. 9469632 - [object Object] (2016-10-18),
2. 8765960 - 6-((S)-1- {1-[5-(2-hydroxy-ethoxy)-pyridin-2-yl]-1H-pyrazol-3-YL}-ethyl)-3H-1,3-benzothiazol-2-one as a tarp-gamma 8 dependent AMPA receptor antagonist (2014-07-01),
3. 8188069 - Azepine derivatives as gamma-secretase inhibitors (2012-05-29),
4. 8058425 - Purine derivatives as kinase inhibitors (2011-11-15),
5. 8022065 - Purine derivatives as kinase inhibitors (2011-09-20),
6. 7390801 - Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds (2008-06-24),
7. 6951854 - Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds (2005-10-04),
8. 6906056 - Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds (2005-06-14),
9. 6888022 - Methods and compounds for inhibiting β-amyloid peptide release and/or its synthesis (2005-05-03),
10. 6861558 - Methods and compounds for inhibiting β-amyloid peptide release and/or its synthesis (2005-03-01),
11. 6683075 - Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting &bgr;-amyloid peptide release and/or its synthesis by use (2004-01-27),
12. 6667305 - Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting &bgr;-amyloid peptide release and/or its synthesis by use of such compounds (2003-12-23),
13. 6653303 - Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting &bgr;-amyloid peptide release and/or its synthesis by use of such compounds (2003-11-25),
14. 6635632 - Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting &bgr;-amyloid peptide release and/or its synthesis by use of such compounds (2003-10-21),
15. 6632811 - Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting &bgr;-amyloid peptide release and/or its synthesis by use of such compounds (2003-10-14),

Title: The Innovative Mind of Jon Kevin Reel: A Journey Through Patents and Pharmaceutical Advancements

Introduction: Jon Kevin Reel, a prolific inventor based in Carmel, IN, has made significant contributions to the pharmaceutical industry through his 45 patents. His innovative spirit and dedication to research have led to the development of groundbreaking compounds that promise advancements in medical therapies.

Latest Patents: Jon Kevin Reel's latest patents focus on AMPA receptor antagonists, particularly a TARP γ8 dependent AMPA receptor antagonist. This involves complex formulas and pharmaceutical applications, including compounds such as 6-((S)-1-{1-[5-(2-hydroxy-ethoxy)-pyridin-2-yl]-1H-pyrazol-3-YL}-ethyl)-3H-1,3-benzothiazol-2-one. These patents detail the compounds’ pharmaceutical acceptable salts, uses, and methods for preparation, highlighting the potential impact of his work on medical treatments.

Career Highlights: Throughout his career, Jon has worked for esteemed companies, including Eli Lilly and Company. His role at such an influential organization allowed him to collaborate on essential research projects and contribute to the development of new medicinal therapies, pushing the boundaries of pharmaceutical science.

Collaborations: Jon's professional journey includes collaboration with notable colleagues such as Warren Jaye Porter and Celia A Whitesitt. These partnerships have fostered a creative environment that has led to numerous innovations and advancements in the field of pharmaceutical research.

Conclusion: Jon Kevin Reel's impressive portfolio of 45 patents underscores his commitment to innovation and excellence in the pharmaceutical industry. His work with cutting-edge AMPA receptor antagonists reflects the profound impact his inventions can have on the future of medicine. As he continues to explore new horizons in drug development, Jon remains a vital contributor to advancements that could transform therapeutic practices and improve patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…